Tags

Type your tag names separated by a space and hit enter

Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease.
J Am Coll Cardiol. 2001 Mar 01; 37(3):775-9.JACC

Abstract

OBJECTIVES

This study was designed to establish the clinical significance of antibodies against oxidized low density lipoprotein (anti-Ox-LDL) titer in atherosclerotic coronary artery disease (CAD).

BACKGROUND

Oxidative modification of LDL, which plays a key role in the development of atherosclerosis, induces immunogenic epitopes in the LDL molecule, and the presence of anti-Ox-LDL has been demonstrated in human sera.

METHODS

Anti-Ox-LDL titer was measured by enzyme-linked immunosorbent assay in 108 patients who had angiographically verified CAD, and 31 patients who had chest pain but no significant CAD, as controls.

RESULTS

The anti-Ox-LDL titer was higher (p < 0.01) in patients with multivessel CAD (19.4 +/- 10.1 AcU/ml, n = 68) than in the controls (9.8 +/- 4.1). However, no significant difference was shown between the single-vessel CAD group (15.1 +/- 6.4, n = 40) and the controls, or between the multivessel CAD group and the single-vessel CAD group. The titer was higher in patients with unstable angina (21.5 +/- 11.8 AcU/ml, n = 20, p < 0.01), or in patients with acute myocardial infarction (23.1 +/- 12.0, n = 20, p < 0.01) than in patients with stable-effort angina or old myocardial infarction (12.2 +/- 8.6, n = 68). Multiple logistic regression analysis indicated that the anti-Ox-LDL titer most powerfully discriminated CAD patients from controls (odds ratio [OR]: 1.20, 95% confidence interval [CI]: 1.07-1.33, p = 0.0006) and acute coronary syndrome from chronic CAD (OR: 1.09, 95% CI: 1.04-1.14, p = 0.0008).

CONCLUSIONS

Serum anti-Ox-LDL titer not only can predict a presence of atherosclerotic CAD but also may be a marker of plaque instability. Low density lipoprotein oxidation may play an important role in the development of plaque instability.

Authors+Show Affiliations

Department of Cardiology, Koshigaya Hospital, Dokkvo University School of Medicine, Saitama, Japan. inouet@dokkyomed.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11693751

Citation

Inoue, T, et al. "Clinical Significance of Antibody Against Oxidized Low Density Lipoprotein in Patients With Atherosclerotic Coronary Artery Disease." Journal of the American College of Cardiology, vol. 37, no. 3, 2001, pp. 775-9.
Inoue T, Uchida T, Kamishirado H, et al. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol. 2001;37(3):775-9.
Inoue, T., Uchida, T., Kamishirado, H., Takayanagi, K., Hayashi, T., & Morooka, S. (2001). Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. Journal of the American College of Cardiology, 37(3), 775-9.
Inoue T, et al. Clinical Significance of Antibody Against Oxidized Low Density Lipoprotein in Patients With Atherosclerotic Coronary Artery Disease. J Am Coll Cardiol. 2001 Mar 1;37(3):775-9. PubMed PMID: 11693751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. AU - Inoue,T, AU - Uchida,T, AU - Kamishirado,H, AU - Takayanagi,K, AU - Hayashi,T, AU - Morooka,S, PY - 2001/11/6/pubmed PY - 2002/1/5/medline PY - 2001/11/6/entrez SP - 775 EP - 9 JF - Journal of the American College of Cardiology JO - J Am Coll Cardiol VL - 37 IS - 3 N2 - OBJECTIVES: This study was designed to establish the clinical significance of antibodies against oxidized low density lipoprotein (anti-Ox-LDL) titer in atherosclerotic coronary artery disease (CAD). BACKGROUND: Oxidative modification of LDL, which plays a key role in the development of atherosclerosis, induces immunogenic epitopes in the LDL molecule, and the presence of anti-Ox-LDL has been demonstrated in human sera. METHODS: Anti-Ox-LDL titer was measured by enzyme-linked immunosorbent assay in 108 patients who had angiographically verified CAD, and 31 patients who had chest pain but no significant CAD, as controls. RESULTS: The anti-Ox-LDL titer was higher (p < 0.01) in patients with multivessel CAD (19.4 +/- 10.1 AcU/ml, n = 68) than in the controls (9.8 +/- 4.1). However, no significant difference was shown between the single-vessel CAD group (15.1 +/- 6.4, n = 40) and the controls, or between the multivessel CAD group and the single-vessel CAD group. The titer was higher in patients with unstable angina (21.5 +/- 11.8 AcU/ml, n = 20, p < 0.01), or in patients with acute myocardial infarction (23.1 +/- 12.0, n = 20, p < 0.01) than in patients with stable-effort angina or old myocardial infarction (12.2 +/- 8.6, n = 68). Multiple logistic regression analysis indicated that the anti-Ox-LDL titer most powerfully discriminated CAD patients from controls (odds ratio [OR]: 1.20, 95% confidence interval [CI]: 1.07-1.33, p = 0.0006) and acute coronary syndrome from chronic CAD (OR: 1.09, 95% CI: 1.04-1.14, p = 0.0008). CONCLUSIONS: Serum anti-Ox-LDL titer not only can predict a presence of atherosclerotic CAD but also may be a marker of plaque instability. Low density lipoprotein oxidation may play an important role in the development of plaque instability. SN - 0735-1097 UR - https://www.unboundmedicine.com/medline/citation/11693751/Clinical_significance_of_antibody_against_oxidized_low_density_lipoprotein_in_patients_with_atherosclerotic_coronary_artery_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(00)01199-2 DB - PRIME DP - Unbound Medicine ER -